TY - JOUR
T1 - Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease
AU - Rab, Minke A E
AU - Kanne, Celeste K
AU - Boisson, Camille
AU - Bos, Jennifer
AU - van Oirschot, Brigitte A
AU - Houwing, Maite
AU - Renoux, Céline
AU - Bartels, Marije
AU - Rijneveld, Anita W
AU - Nur, Erfan
AU - Cnossen, Marjon H
AU - Joly, Philippe
AU - Nader, Elie
AU - Fort, Romain
AU - Connes, Philippe
AU - van Wijk, Richard
AU - Sheehan, Vivien A
AU - van Beers, Eduard J
N1 - Publisher Copyright:
© 2024 by The American Society of Hematology.
PY - 2024/1/23
Y1 - 2024/1/23
N2 - We investigated the potential of the point of sickling (PoS; the pO2 tension at which red cells start to sickle), determined by oxygen gradient ektacytometry to serve as a biomarker associated with the incidence of acute sickle cell disease-related complications in 177 children and 50 adults. In the pediatric cohort, for every 10 mmHg increase in PoS reflecting a greater likelihood of sickling, the likelihood of an individual experiencing >1 type of acute complication increased; the adjusted odds ratio (aOR) was 1.65. For every 0.1 increase in minimum elongation index (EImin; reflecting improved red blood cell deformability at hypoxia), the aOR was 0.50. In the adult cohort, for every 10 mmHg increase in PoS, we found an aOR of 3.00, although this was not significant after correcting for multiple testing. There was a trend for an association between higher PoS and greater likelihood of vaso-occlusive episodes (VOEs; children aOR, 1.35; adults aOR, 2.22). In children, only EImin was associated with VOEs (aOR, 0.68). When data of both cohorts were pooled, significant associations with PoS and/or EImin were found for all acute complications, independently and when >1 type of acute complication was assessed. These findings indicate that oxygen gradient ektacytometry generates novel biomarkers and provides a rationale for further development of these biomarkers in the assessment of clinical severity, evaluation of novel therapies, and as surrogate clinical trial end points. These biomarkers may be useful in assessing efficacy of novel therapies like pyruvate kinase activators, voxelotor, and L-glutamine.
AB - We investigated the potential of the point of sickling (PoS; the pO2 tension at which red cells start to sickle), determined by oxygen gradient ektacytometry to serve as a biomarker associated with the incidence of acute sickle cell disease-related complications in 177 children and 50 adults. In the pediatric cohort, for every 10 mmHg increase in PoS reflecting a greater likelihood of sickling, the likelihood of an individual experiencing >1 type of acute complication increased; the adjusted odds ratio (aOR) was 1.65. For every 0.1 increase in minimum elongation index (EImin; reflecting improved red blood cell deformability at hypoxia), the aOR was 0.50. In the adult cohort, for every 10 mmHg increase in PoS, we found an aOR of 3.00, although this was not significant after correcting for multiple testing. There was a trend for an association between higher PoS and greater likelihood of vaso-occlusive episodes (VOEs; children aOR, 1.35; adults aOR, 2.22). In children, only EImin was associated with VOEs (aOR, 0.68). When data of both cohorts were pooled, significant associations with PoS and/or EImin were found for all acute complications, independently and when >1 type of acute complication was assessed. These findings indicate that oxygen gradient ektacytometry generates novel biomarkers and provides a rationale for further development of these biomarkers in the assessment of clinical severity, evaluation of novel therapies, and as surrogate clinical trial end points. These biomarkers may be useful in assessing efficacy of novel therapies like pyruvate kinase activators, voxelotor, and L-glutamine.
UR - http://www.scopus.com/inward/record.url?scp=85183005326&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2023011013
DO - 10.1182/bloodadvances.2023011013
M3 - Article
C2 - 37976458
SN - 2473-9529
VL - 8
SP - 276
EP - 286
JO - Blood Advances
JF - Blood Advances
IS - 2
ER -